Author: Darrell Miller
Calcium is the most damaging mineral that is involved in the calcification of the blood vessel system. Ionic calcium, which is a floating form of calcium, is used by the body in daily functions like muscle contraction and relaxation, nerve impulse transmission, blood coagulation, and others. Calcium is a mineral that is capable of forming complexes with other components, such as proteins. These complexes can eventually lead to the formation of lesions, plaque, and the overall hardening of the blood vessels.
There are four different components that are found mainly in arterial walls which often combine with calcium. Elastin, a type of protein that makes up a good amount of the blood vessel wall, is the substance that allows the arterial wall to be elastic. During the process leading to atherosclerosis, elastin often forms complexes with ionic calcium, which results in a loss of elasticity.
Collagen, another type of protein that works with elastin to make up the bulk of arterial walls, forms complexes with ionic calcium, which leads to hardening of the blood vessel. MPCs, which are carbohydrates that contain a number of agents including amino acids, uronic acids, and chondroitin sulfate, are found within the arterial wall where they form complexics with ionic calcium to promote the formation of atherosclerosis. Beta lipoproteins and pre-beta lipoproteins transport a fatty acid and glycerol combination for storage in the liver, muscles, and other areas of the body.
Although beta and pre-beta lipoproteins form ionic calcium complexes and initiate the onset of arteriosclerosis, there are lipoproteins that do not form complexes with calcium, but interferes with the formation of ionic calcium complexes instead. It is clear that ionic calcium plays a huge role in the formation of arterial plaque and the actual hardening of arteries, due to the complexes it forms with components of the arterial wall. Because EDTA effectively ties up calcium complexes so that it can be eliminated through the urine, it is also clear why EDTA chelation therapy is a successful way to reduce the levels of atherosclerotic plaque and reverse the hardened condition that so often occurs in the artery walls.
EDTA chelation therapy was patented in Germany in 1930 and first used in medicine in 1941 to help with lead poisoning. It wasn't patented in the United States until 1949, with several papers being published on its therapeutic effects following in the early 1950s. EDTA chelation therapy has been used in the U.S. to treat atherosclerosis since 1952, but was also used for lead poisoning and heavy metal toxicity before that. After its initial use for lead and heavy metal poising, it was noted that EDTA resulted in the reduction of severe pressure and pain in and around the chest, which led to the discovery of its abilities to treat atherosclerosis.
Since then, thousands of scientific articles have been written concerning the many aspects of EDTA chelation therapies as well as its safety, which has been proven by its use on thousands of patients in over three million intravenous treatments by over one thousand doctors in the last fifty years. Not one fatality has been documented when established protocol has been followed, while the FDA approved the new drug application for EDTA without requiring any additional safety studies to determine its safe use. Have you tried oral EDTA?
More information on EDTA supplements is available at VitaNet ®, LLC Health Food Store. http://vitanetonline.com/